Healthcare provider profile · identity verified

Stephanie Mathews, ARNP

Nurse Practitioner · NAPLES, FL · NPI 1255588794

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	492	82
Eliquis	Apixaban	272	30
Amlodipine Besylate	Amlodipine Besylate	239	37
Furosemide	Furosemide	216	35
Gabapentin	Gabapentin	211	39
Levothyroxine Sodium	Levothyroxine Sodium	198	26
Potassium Chloride	Potassium Chloride	191	30
Metoprolol Tartrate	Metoprolol Tartrate	161	28
Clopidogrel	Clopidogrel Bisulfate	151	22
Lisinopril	Lisinopril	121	22
Levetiracetam	Levetiracetam	119	12
Losartan Potassium	Losartan Potassium	116	27
Tamsulosin Hcl	Tamsulosin Hcl	114	23
Divalproex Sodium	Divalproex Sodium	103	16
Metformin Hcl	Metformin Hcl	103	14
Carvedilol	Carvedilol	92	17
Donepezil Hcl	Donepezil Hcl	90	16
Sertraline Hcl	Sertraline Hcl	85	15
Xarelto	Rivaroxaban	84	suppressed
Omeprazole	Omeprazole	79	19
Metoprolol Succinate	Metoprolol Succinate	77	18
Trazodone Hcl	Trazodone Hcl	77	13
Megestrol Acetate	Megestrol Acetate	76	26
Quetiapine Fumarate	Quetiapine Fumarate	73	12
Tresiba Flextouch U-100	Insulin Degludec	72	suppressed
Trulicity	Dulaglutide	71	12
Torsemide	Torsemide	66	12
Memantine Hcl	Memantine Hcl	64	16
Finasteride	Finasteride	59	11
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	54	15
Gemtesa	Vibegron	52	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	52	suppressed
Simvastatin	Simvastatin	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	47	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	47	28
Fiasp Flextouch	Insulin Aspart (Niacinamide)	44	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	44	22
Pantoprazole Sodium	Pantoprazole Sodium	43	15
Tradjenta	Linagliptin	43	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	40	suppressed
Famotidine	Famotidine	39	13
Hydralazine Hcl	Hydralazine Hcl	39	suppressed
Lactulose	Lactulose	39	suppressed
Spironolactone	Spironolactone	38	suppressed
Sucralfate	Sucralfate	38	suppressed
Alendronate Sodium	Alendronate Sodium	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	37	suppressed
Ozempic	Semaglutide	37	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	36	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Methocarbamol	Methocarbamol	35	17
Mirtazapine	Mirtazapine	35	suppressed
Xifaxan	Rifaximin	35	suppressed
Jardiance	Empagliflozin	33	suppressed
Nifedipine Er	Nifedipine	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	32	12
Januvia	Sitagliptin Phosphate	32	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	31	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	suppressed
Risperidone	Risperidone	31	suppressed
Allopurinol	Allopurinol	30	suppressed
Tramadol Hcl	Tramadol Hcl	29	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Entresto	Sacubitril/Valsartan	27	suppressed
Benztropine Mesylate	Benztropine Mesylate	26	suppressed
Enulose	Lactulose	26	suppressed
Linzess	Linaclotide	26	suppressed
Prednisone	Prednisone	26	11
Digoxin	Digoxin	25	suppressed
Humalog Kwikpen U-100	Insulin Lispro	25	suppressed
Meloxicam	Meloxicam	25	suppressed
Movantik	Naloxegol Oxalate	25	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	25	suppressed
Ceftriaxone	Ceftriaxone Sodium	24	16
Latanoprost	Latanoprost	24	suppressed
Memantine Hcl Er	Memantine Hcl	24	suppressed
Olanzapine	Olanzapine	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Belsomra	Suvorexant	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	21	11
Fiasp	Insulin Aspart (Niacinamide)	20	suppressed
Incruse Ellipta	Umeclidinium Bromide	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	13
Topiramate	Topiramate	20	suppressed
Constulose	Lactulose	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Amiodarone Hcl	Amiodarone Hcl	18	suppressed
Levofloxacin	Levofloxacin	18	14
Brimonidine Tartrate	Brimonidine Tartrate	17	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	16	suppressed
Jentadueto	Linagliptin/Metformin Hcl	16	suppressed
Fluconazole	Fluconazole	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Vascepa	Icosapent Ethyl	15	suppressed
Albuterol Sulfate	Albuterol Sulfate	14	11
Alprazolam	Alprazolam	14	suppressed
Atenolol	Atenolol	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Haloperidol	Haloperidol	14	suppressed
Lubiprostone	Lubiprostone	14	suppressed
Mupirocin	Mupirocin	14	11
Pregabalin	Pregabalin	14	suppressed
Retacrit	Epoetin Alfa-Epbx	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Calcium Acetate	Calcium Acetate	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Dovato	Dolutegravir Sodium/Lamivudine	13	suppressed
Fenofibrate	Fenofibrate,micronized	13	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	13	12
Santyl	Collagenase Clostridium Hist.	13	suppressed
Tadalafil	Tadalafil	13	suppressed
Baclofen	Baclofen	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Levetiracetam Er	Levetiracetam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error